scispace - formally typeset
Open AccessJournal ArticleDOI

Inhibition of the CDK9‒cyclin T1 protein‒protein interaction as a new approach against triple-negative breast cancer

Reads0
Chats0
TLDR
In this paper, the authors designed and generated a library of metal complexes bearing the 7-chloro-2-phenylquinoline CˆN ligand and tested their activity against the CDK9-cyclin T1 PPI.
About
This article is published in Acta Pharmaceutica Sinica B.The article was published on 2021-10-30 and is currently open access. It has received 25 citations till now. The article focuses on the topics: Triple-negative breast cancer & Cancer research.

read more

Citations
More filters
Journal ArticleDOI

Berberine as a potential agent for breast cancer therapy

TL;DR: The evidence for BBR in BC therapy is provided, its detailed underlying mechanism in BC treatment remains unclear, and the novel BBR-based therapeutic strategies against BC improve biocompatibility and water solubility.
Journal ArticleDOI

Identification of a cytisine-based EED-EZH2 protein-protein interaction inhibitor preventing metastasis in triple-negative breast cancer cells

TL;DR: To the authors' knowledge, compound 1 is the first cytisine-based EED-EZH2 PPI inhibitor preventing metastasis in TNBC cells, and may provide a new avenue for the development of more efficacious E ED-EzH 2 PPI inhibitors in T NBC treatment.
Journal ArticleDOI

A state-of-the-art review on LSD1 and its inhibitors in breast cancer: Molecular mechanisms and therapeutic significance

TL;DR: This review will provide insight into the overview structure of LSD1, summarize its action mechanisms in BC, describe the therapeutic potential ofLSD1 inhibitors inBC, and prospect the current opportunities and challenges of targeting LSD1 for BC therapy.
Journal ArticleDOI

Targeting PGAM1 in cancer: An emerging therapeutic opportunity.

TL;DR: In this paper , the authors provide insights into structure, function, and regulation of PGAM1, summarizes its mechanism in tumorigenesis, and reviews the advanced status of the PGAM-1 inhibitors in cancer diagnosis and treatment.
References
More filters
Journal ArticleDOI

Kinase-targeted cancer therapies: progress, challenges and future directions

TL;DR: The human genome encodes 538 protein kinases that transfer a γ-phosphate group from ATP to serine, threonine, or tyrosine residues, which are the second most targeted group of drug targets, after the G-protein-coupled receptors.
Journal ArticleDOI

Targeting oncogenic Myc as a strategy for cancer treatment

TL;DR: Current strategies include indirectly targeting myc by inhibiting its regulation and stability, and interaction with its partner Max, which is necessary for its regulation of gene expression, which provides promise for effective therapeutics against myc-dependent cancers.
Journal ArticleDOI

Targeting cancer with kinase inhibitors

TL;DR: There are numerous prospects for the discovery of novel kinase targets, and cancer immunotherapy is explored as a new and promising research area for studying kinase biology.
Related Papers (5)